HeartFlow (HTFL): Can the Stock Reach $70 After Its +105% Year-to-Date Advance?

Key Takeaways

• The $70 level is not an analyst consensus target but a round-number technical and psychological objective discussed publicly after the stock broke above its 52-week high.
• With the latest price near $59–$60, a move to $70 would require roughly 17%–18% upside, a meaningful advance rather than a small step.
• Nine analysts tracked by S&P Global give the stock a “Strong Buy” average rating, yet their mean price target of $50.50 sits below the current price, with individual targets ranging from about $37 to $64.
• Key supports include revenue growth of roughly 40% or more, raised fiscal 2026 guidance, and positive clinical data for the company’s AI-powered coronary artery disease platform.
• Major risks involve ongoing net losses, a valuation that has outrun most Street targets, high volatility with a beta near 1.9, and uncertainty around competition and reimbursement.
• Investors can review additional details on Major News, Today’s Price Move, the Forecast, and Earnings pages.

What the Analyst Consensus Shows

Because the averaged analyst targets sit at $50.50—below the current price—the $70 figure serves as a publicly discussed technical objective rather than a formal consensus. That round-number goal surfaces in market commentary once the shares clear the 52-week high of $60.65. The analyst data remains relevant, however. Piper Sandler’s Matt O’Brien holds the highest target at $64 with an Overweight rating, recently raised from $45. Canaccord Genuity’s William Plovanic maintains a Buy rating and $56 target, while UBS initiated with Neutral and $55 in September 2026. Other firms such as Morgan Stanley, Baird, Stifel, and JPMorgan cluster between $40 and $45, and Wells Fargo sits near $37. The wide spread highlights differing views on how much of the rally is sustainable.

Where the Stock Stands Today

Trading near $59–$60, HTFL sits just below its 52-week high of $60.65 and well above the low of $20.13. Reaching $70 would represent an approximate 17%–18% gain, which would depend on continued fundamental progress rather than simple momentum. Trailing twelve-month revenue stands around $212 million, up more than 40%, and the company raised its fiscal 2026 revenue outlook to $228–$232 million. The business still reports a trailing net loss near $118 million and negative earnings per share, so any further advance will hinge on sustained growth and eventual margin improvement.

Factors That Could Support Further Gains

• Accelerating adoption of the AI-powered FFRct and Plaque analyses, backed by revenue growth above 40% and raised guidance.
• Positive clinical momentum, including data shared at the American Heart Association and results from the randomized P4 trial published in the New England Journal of Medicine.
• Analyst upgrades and target increases through 2026, even as the aggregate target trails the share price.
• Investor interest in AI-enabled medtech, reflected in elevated trading volume and relative strength.

Obstacles That Could Limit Upside

• Persistent losses and the absence of a clear near-term profitability path could constrain valuation multiples.
• After a roughly +105% advance over the past year, the average analyst target now sits about 15% below the current price, signaling stretched expectations.
• A beta near 1.9 implies the potential for sharp pullbacks on any disappointing results or guidance revisions.
• Competition in AI-driven cardiac diagnostics and possible reimbursement or regulatory challenges could temper adoption rates.

Technical Levels to Watch

Immediate resistance remains the 52-week high at $60.65; a decisive close above that level would open the door to round-number targets at $65 and $70. Support lies in the $55–$57 area, with additional cushion near $52 where buyers stepped in during a recent pullback. The longer-term trend stays upward, yet the stock’s inability to hold firmly above $60 keeps that resistance level in focus. I also checked this using Tickeron’s AI Screener to compare relative strength within the sector.

Time Horizon and Key Items to Monitor

Analyst targets generally reflect a 12-month horizon, and the $70 objective should be viewed in that same medium-term context. Investors will want to track quarterly revenue trends and guidance updates, gross margin progress, any further analyst target revisions, reimbursement developments, and price action around the $60.65 resistance and $55–$57 support. Broader rate expectations and risk appetite for high-beta growth names also play a role. From what I see, monitoring these elements alongside technical signals helps maintain perspective on the setup.

Using AI Daily Buy/Sell Signals in Practice

In my own research process, I frequently review Tickeron’s AI Daily Buy/Sell Signals to gain a systematic perspective on names like this one. The platform applies artificial intelligence to scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market conditions. This approach helps me identify potential shifts more efficiently while complementing fundamental work, offering a rules-based layer that fits alongside other analysis tools.

Final Assessment

The $70 objective for HTFL represents a technically grounded milestone rather than an analyst consensus, and achieving it would require a substantial 17%–18% rise from current levels. Support stems from strong revenue growth, raised guidance, and encouraging clinical results, while continued losses, a valuation ahead of the average target, and elevated volatility remain the main hurdles. With analyst targets spanning roughly $37 to $64 and a mean below the market price, views differ markedly. The next meaningful signals will likely come from quarterly results, guidance updates, and whether the stock can sustain a move above its 52-week high.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume